Business
Moleculin Reports Second Quarter 2023 Financial Results
– Ongoing progress across ongoing clinical development programs with growing body of positive preclinical and clinical data – Released Clinical Trial Update
About this update from Moleculin Biotech, Inc.
[{"type":"text","content":"– Ongoing progress across ongoing clinical development programs with growing body of positive preclinical and clinical data\n– Released Clinical Trial Update press release yesterday providing the quarter's update on its clinical activities\n– Company to host conference call and webcast today at 8:30 AM ET\nHOUSTON, Aug. 11, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (\"Moleculin\" or the \"Company\"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today reported its financial results for the quarter ended June 30, 2023. As previously announced, the Company will host a conference call and live audio webcast, today, August 11, 2023, at 8:30 AM ET (details below).\n\n \n \n \n \n \n \n\n \n\"We have continued our operational execution and clinical progress over the past quarter,\" commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin. \"We remain focused advancing our priority pipeline programs to key data milestones in the near term. We firmly believe we are well positioned not only to unlock significant potential for all stakeholders but, importantly, address the medical unmet needs of people with highly resistant cancers and viruses.\"\nRecent Highlights \nReleased yesterday a press release Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones providing an update on its clinical update for the quarter:Reported preliminary efficacy data on its Phase 1B/2 clinical trial with Annamycin in monotherapy treatment of soft tissue sarcoma metastasized to the lungs with 73% (n=26) of the subjects exhibiting stable disease after two cycles of treatmentAnnounced successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML (MB-106) and opens the Phase 2 portion for recruitmentAnnounced a preliminary CR/CRi rate of 33% (n=6) in the Phase 1B portion of its MB-106 clinical trialAnnounced that the Company is investigating potential naked short selling of its stock and has retained well-known analytics firm, Shareholder Intelligence Services, LLC; andAnnounced the publication of data from successful European Phase 1 clinical trial evaluating Annamycin as single agent treatment of relapsed or ref...